Hospital & Healthcare Services · Founded 1993 · www.dhanvantrihospital.in · BSE 531043 · · ISIN INE239F01015
No Notes Added Yet
Business
Dhanvantri Jeevan Rekha Ltd. operates in the Hospital & Healthcare Services sector in India. Its core business model likely involves providing a range of medical services, including inpatient and outpatient care, diagnostic services, surgical procedures, emergency care, and potentially specialized treatments. The company generates revenue primarily through fees charged for these medical services, which include consultations, room charges, procedure fees, pharmacy sales, and diagnostic tests to patients, either directly or via insurance providers and government schemes.
Revenue Mix
While specific breakdowns are not available, typical revenue streams for a hospital and healthcare services company like Dhanvantri Jeevan Rekha Ltd. would include:
Inpatient Services: Revenue from patient admissions, surgeries, long-term care, and associated room and board charges.
Outpatient Services: Income from consultations, day-care procedures, and minor treatments.
Diagnostic Services: Fees from lab tests, imaging (X-rays, MRI, CT scans), and other diagnostic procedures.
Pharmacy & Allied Services: Sales of medicines, medical supplies, and other ancillary services.
Emergency & Critical Care: Revenue from urgent care and intensive care units.
Industry
The Indian healthcare services industry is characterized by significant growth, driven by a large and growing population, increasing disposable incomes, rising health awareness, and a growing prevalence of lifestyle diseases. It is a fragmented market with a mix of large corporate hospital chains, regional hospital groups, single-specialty hospitals, and standalone clinics. Without specific operational details, Dhanvantri Jeevan Rekha Ltd. likely positions itself based on factors such as geographic location, specialty focus (e.g., multi-specialty, cardiology, orthopedics), service quality, technology infrastructure, and pricing strategy within its target markets.
MOAT
Potential competitive advantages for a hospital and healthcare services provider often stem from:
Brand Reputation & Trust: A strong reputation for quality medical outcomes, patient care, and ethical practices.
Physician Network: The ability to attract and retain highly skilled and renowned doctors, which directly impacts patient inflow.
Specialized Infrastructure: Investments in advanced medical technology and facilities for complex procedures.
Geographic Dominance: Being the leading healthcare provider in a specific region or locality, creating convenience for patients.
Switching Costs: For patients with chronic conditions or those requiring long-term care, switching hospitals can be inconvenient.
Growth Drivers
Key factors that can drive growth for Dhanvantri Jeevan Rekha Ltd. over the next 3-5 years include:
Demographic Shifts: India's large and aging population and increasing prevalence of chronic diseases.
Rising Healthcare Expenditure: Growth in public and private spending on healthcare.
Medical Tourism: Leveraging India's cost-effective quality healthcare to attract international patients.
Technological Advancements: Adoption of new medical technologies and digital health solutions (e.g., telemedicine, AI diagnostics).
Government Initiatives: Policy support and schemes aimed at expanding healthcare access and insurance penetration (e.g., Ayushman Bharat).
Expansion: Opening new facilities or expanding existing capacities in underserved or high-growth areas.
Risks
Regulatory & Policy Changes: Evolving government regulations regarding pricing, quality standards, and healthcare reforms.
Intense Competition: Competition from existing large hospital chains, new entrants, and regional players.
Talent Retention: Challenges in attracting and retaining qualified doctors, nurses, and allied healthcare professionals.
Capital Expenditure Needs: The healthcare sector is capital-intensive, requiring continuous investment in infrastructure, technology, and upgrades.
Medical Malpractice & Litigation Risks: Exposure to legal challenges related to patient care and outcomes.
Insurance Reimbursement Issues: Delays or reductions in payments from public and private insurance providers.
Economic Downturns: Reduced discretionary spending on healthcare during economic contractions.
Management & Ownership
As a listed entity (DHAN JEEVAN), Dhanvantri Jeevan Rekha Ltd. would typically have a professional management team overseen by a Board of Directors. The ownership structure would likely involve promoter holdings, institutional investors, and public shareholders. Without specific names or details, it's presumed that the promoters and management would be responsible for strategic direction, operational efficiency, and financial performance within the highly regulated healthcare environment.
Outlook
Dhanvantri Jeevan Rekha Ltd. operates within a fundamentally strong and growing sector in India, driven by favorable demographics and increasing healthcare awareness. The long-term demand for quality healthcare services provides a significant tailwind for growth. However, the company faces inherent challenges common to the industry, including intense competition, the need for continuous capital investment in technology and infrastructure, regulatory complexities, and the constant demand for highly skilled medical professionals. Success will depend on its ability to differentiate through service quality, strategic expansion, efficient cost management, and adept navigation of the regulatory landscape.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 5 | 6 | 5 | 6 | 6 | 6 | 6 | 7 | 7 | 8 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 7 | 7 | 8 |
| Total Expenditure | 5 | 5 | 5 | 6 | 6 | 5 | 6 | 7 | 7 | 8 |
| Operating Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 |
| Provision for Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Tax | -0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | -0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 |
| Adjusted Earnings Per Share | -0.2 | 0.4 | 0.4 | 0.4 | 0.1 | 0.1 | -0.3 | 0.4 | 0.7 | 0.4 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 8 | 9 | 11 | 14 | 17 | 18 | 10 | 17 | 18 | 20 | 23 | 28 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income | 8 | 10 | 12 | 14 | 17 | 18 | 10 | 17 | 18 | 21 | 23 | 28 |
| Total Expenditure | 6 | 8 | 10 | 12 | 16 | 18 | 11 | 15 | 17 | 20 | 22 | 28 |
| Operating Profit | 2 | 2 | 2 | 2 | 1 | 1 | -1 | 2 | 1 | 1 | 1 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 2 | 1 | 1 | 1 | 0 | -0 | -2 | 1 | -0 | 0 | 1 | 0 |
| Provision for Tax | 0 | 0 | 0 | -0 | 0 | -0 | -0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Tax | 1 | 1 | 1 | 1 | 0 | -0 | -1 | 0 | -0 | 0 | 1 | 0 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 1 | 1 | 1 | 1 | 0 | -0 | -1 | 0 | -0 | 0 | 1 | 0 |
| Adjusted Earnings Per Share | 2.6 | 2.3 | 1.3 | 1.8 | 0.1 | -0.6 | -3.5 | 1.2 | -0.5 | 0.4 | 1.2 | 1.2 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 15% | 11% | 5% | 11% |
| Operating Profit CAGR | 0% | -21% | 0% | -7% |
| PAT CAGR | 0% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -27% | 24% | 19% | -2% |
| ROE Average | 5% | 2% | -1% | 3% |
| ROCE Average | 6% | 2% | -0% | 5% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 8 | 9 | 10 | 11 | 11 | 10 | 9 | 10 | 9 | 9 | 10 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 |
| Total Current Liabilities | 2 | 2 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 3 |
| Total Liabilities | 11 | 13 | 16 | 16 | 15 | 15 | 14 | 14 | 14 | 15 | 15 |
| Fixed Assets | 5 | 5 | 12 | 12 | 11 | 11 | 10 | 9 | 9 | 8 | 8 |
| Other Non-Current Assets | 2 | 3 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 1 | 2 |
| Total Current Assets | 4 | 4 | 3 | 3 | 3 | 3 | 2 | 4 | 4 | 6 | 5 |
| Total Assets | 11 | 13 | 16 | 16 | 15 | 15 | 14 | 14 | 14 | 15 | 15 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 2 | 1 | 3 |
| Cash Flow from Operating Activities | 1 | 1 | 4 | 1 | 1 | 1 | -0 | 1 | -0 | 3 | -0 |
| Cash Flow from Investing Activities | -1 | -1 | -4 | -1 | -0 | -0 | -0 | -0 | -1 | -0 | -1 |
| Cash Flow from Financing Activities | 0 | 0 | 1 | -0 | -2 | -0 | -0 | -0 | 0 | 0 | 0 |
| Net Cash Inflow / Outflow | -0 | 0 | 0 | 0 | -1 | 1 | -0 | 1 | -1 | 3 | -1 |
| Closing Cash & Cash Equivalent | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 2 | 1 | 3 | 3 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 2.61 | 2.33 | 1.33 | 1.78 | 0.11 | -0.64 | -3.47 | 1.2 | -0.53 | 0.4 | 1.23 |
| CEPS(Rs) | 3.49 | 2.98 | 2.24 | 4.47 | 2.86 | 2.04 | -0.92 | 3.68 | 1.8 | 2.52 | 2.61 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 20.48 | 22.8 | 24.14 | 25.91 | 26.03 | 25.38 | 21.91 | 23.11 | 22.58 | 22.98 | 24.58 |
| Core EBITDA Margin(%) | 19.22 | 15.64 | 10.42 | 13.49 | 7.32 | 3.65 | -7.66 | 8.9 | 3.28 | 4.08 | 3.17 |
| EBIT Margin(%) | 20.14 | 16.12 | 10.22 | 6.49 | 1.37 | -1.5 | -16.45 | 4.11 | -0.78 | 1.28 | 2.51 |
| Pre Tax Margin(%) | 19.12 | 15.24 | 8.65 | 4.9 | 0.69 | -1.74 | -16.67 | 4.01 | -0.82 | 1.25 | 2.45 |
| PAT Margin (%) | 13.4 | 10.3 | 4.89 | 5.3 | 0.28 | -1.45 | -14.55 | 2.92 | -1.23 | 0.81 | 2.23 |
| Cash Profit Margin (%) | 17.95 | 13.19 | 8.22 | 13.32 | 6.97 | 4.59 | -3.87 | 8.98 | 4.18 | 5.04 | 4.73 |
| ROA(%) | 10.82 | 7.95 | 3.77 | 4.46 | 0.3 | -1.76 | -10.03 | 3.51 | -1.54 | 1.15 | 3.4 |
| ROE(%) | 14.25 | 10.75 | 5.68 | 7.1 | 0.44 | -2.51 | -14.69 | 5.31 | -2.31 | 1.77 | 5.19 |
| ROCE(%) | 21.14 | 16.71 | 11.79 | 7.91 | 1.97 | -2.55 | -16.37 | 7.4 | -1.46 | 2.78 | 5.8 |
| Receivable days | 22.61 | 23.41 | 11.64 | 11.41 | 18.47 | 14.93 | 28.42 | 30.28 | 42.97 | 37.5 | 28.6 |
| Inventory Days | 0.42 | 0.49 | 0.49 | 0.88 | 1.74 | 2.21 | 3.71 | 2.23 | 2.67 | 2.38 | 2.24 |
| Payable days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -9882.22 | 0 | 0 |
| PER(x) | 5.85 | 13.11 | 42.55 | 17.02 | 133.1 | 0 | 0 | 13.96 | 0 | 60.76 | 16.73 |
| Price/Book(x) | 0.74 | 1.34 | 2.35 | 1.17 | 0.58 | 0.21 | 0.34 | 0.72 | 0.58 | 1.07 | 0.84 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.75 | 1.29 | 1.99 | 0.96 | 0.37 | 0.06 | 0.23 | 0.3 | 0.25 | 0.32 | 0.26 |
| EV/Core EBITDA(x) | 3.02 | 6.76 | 14.7 | 6.63 | 4.58 | 1.22 | -3.94 | 2.95 | 5.47 | 5.8 | 5.23 |
| Net Sales Growth(%) | 9.82 | 16.08 | 20.63 | 23.04 | 22.53 | 8.16 | -46.28 | 71.42 | 5.49 | 15.7 | 10.69 |
| EBIT Growth(%) | 76.38 | -7.11 | -23.51 | -21.8 | -74.09 | -218.05 | -489.54 | 142.85 | -119.94 | 289.89 | 117.69 |
| PAT Growth(%) | 91.65 | -10.77 | -42.71 | 33.38 | -93.57 | -664.39 | -438.61 | 134.43 | -144.21 | 176.27 | 206.28 |
| EPS Growth(%) | 91.65 | -10.77 | -42.71 | 33.38 | -93.57 | -664.61 | -438.61 | 134.44 | -144.21 | 176.26 | 206.27 |
| Debt/Equity(x) | 0 | 0 | 0 | 0.18 | 0.01 | 0.01 | 0.01 | 0 | 0 | 0 | 0 |
| Current Ratio(x) | 1.83 | 1.94 | 0.78 | 1.03 | 0.8 | 0.91 | 0.81 | 1.21 | 1.24 | 1.44 | 1.49 |
| Quick Ratio(x) | 1.82 | 2.83 | 1.4 | 1.67 | 1.37 | 1.46 | 1.68 | 3.04 | 4.57 | 3.98 | 3.79 |
| Interest Cover(x) | 19.79 | 18.35 | 6.5 | 4.07 | 2.02 | -6.3 | -76.08 | 42.19 | -19.82 | 46.9 | 45.79 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0.16 | 0.02 | 0.05 | 0.02 | 0 | 0 | 0 | 0 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 19.65 | 19.65 | 19.65 | 19.65 | 19.65 | 19.65 | 19.65 | 19.65 | 19.65 | 19.65 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 80.35 | 80.35 | 80.35 | 80.35 | 80.35 | 80.35 | 80.35 | 80.35 | 80.35 | 80.35 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.33 | 0.33 | 0.33 | 0.33 | 0.33 | 0.33 | 0.33 | 0.33 | 0.33 | 0.33 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +15% | +11% | +5% | +11% |
| Operating Profit CAGR | 0% | -21% | 0% | -7% |
| PAT CAGR | — | — | — | 0% |
| Share Price CAGR | -27% | +24% | +19% | -2% |
| ROE Average | +5% | +2% | -1% | +3% |
| ROCE Average | +6% | +2% | 0% | +5% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 19.65 | 19.65 | 19.65 | 19.65 | 19.65 | 19.65 | 19.65 | 19.65 | 19.65 | 19.65 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 80.35 | 80.35 | 80.35 | 80.35 | 80.35 | 80.35 | 80.35 | 80.35 | 80.35 | 80.35 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.33 | 0.33 | 0.33 | 0.33 | 0.33 | 0.33 | 0.33 | 0.33 | 0.33 | 0.33 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.